RE: RNS: Annual IND report14 Apr 2026 09:02
Just shows how crucial involving made was, there's no way we could complete p1 ourselves, at least not without even more horrific dilution.
Im glad VS hasn't updated about if patients are alive or not as that is not the target of phase 1, and to do so would make it seem that patient survival is key to p1 success when it isn't and distract from objectives. Market might not like that, but that's the way it is. The next dose escalation is key, if they can give a full dose without DLT then that's when we'll start movement to £20 and beyond, and hopefully start involving major pharma in the next 18-24 months with a view to phase 2.
A long long way to go yet, but so far, all good.